Clinical Trials · NCT05412004
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 469
- Start date
- Jun 2022
- Locations
- 58 sites, 10 countries
- Primary endpoint
- Change From Baseline in Apnea-Hypopnea Index (AHI)